Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
About this item
Full title
Author / Creator
Reynolds, Harmony R , Adhikari, Samrachana , Pulgarin, Claudia , Troxel, Andrea B , Iturrate, Eduardo , Johnson, Stephen B , Hausvater, Anaïs , Newman, Jonathan D , Berger, Jeffrey S , Bangalore, Sripal , Katz, Stuart D , Fishman, Glenn I , Kunichoff, Dennis , Chen, Yu , Ogedegbe, Gbenga and Hochman, Judith S
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
There is concern that patients taking renin–angiotensin–aldosterone system inhibitors have an increased risk of Covid-19, because angiotensin-converting enzyme 2 is a receptor for the virus. This study showed no increase in likelihood of a positive Covid-19 test or severe Covid-19 in patients taking any of five common classes of antihypertensive dr...
Alternative Titles
Full title
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2414437798
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2414437798
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2008975
